AIM ImmunoTech outlines Phase II study plans for long Covid fatigue
AIM ImmunoTech leadership offers new details on a potential Phase II trial of Ampligen in long Covid patients with chronic…
By
Covid-19
Latest in
Covid-19
Ashvattha previews plans for long Covid trial in mid-2023
In an exclusive, Ashvattha Therapeutics CEO Jeff Cleland discusses a potential trial of OP-101 in long Covid patients experiencing chronic…
By
Frontier reports positive Phase I Covid-19 drug data
In the trial, up to 400mg daily dose of FB2001 was found to be safe and well tolerated.
Novavax begins Phase IIb/III Covid-19 vaccine trial in children
The trial will enrol 3,600 participants in Mexico, US, Argentina, Spain, UK, Colombia, South Africa, Philippines and Brazil.
Ascletis receives FDA nod for Phase Ib Covid-19 oral drug trial
The trial will analyse the safety, tolerability, pharmacokinetics and initial efficacy of ASC10 tablets in Covid-19 patients.
DCRI tasked as data centre for NIH long Covid studies
The institute will partner with RTI International to expedite the trial process and launch multi-intervention studies.
Axcella previews long Covid registrational trial plans in UK and US
Axcella in discussions with UK regulators for a new long Covid trial, CEO says, following Phase IIa results announced this…
By
Tevogen Bio reports positive data from Covid-19 therapy trial
At any dose levels tested, no dose-limiting toxicities or substantial treatment-associated adverse events were reported.